Achaete-scute like (ASCL)2 is a basic helix-loop-helix transcription factor essential for the maintenance of proliferating trophoblasts during placental development. Using oligonucleotide microarrays we identified ascl2 as a gene significantly upregulated in colorectal adenocarcinomas (n ¼ 36 cancers, n ¼ 16 normals; 15-fold, Po0.0001). This finding was confirmed by quantitative reverse transcriptase (RT)-PCR on large intestinal cancers (n ¼ 29 cancers, n ¼ 16 normals; 10-fold, Po0.0001).
Introduction
The achaete-scute like (ascl) genes belong to a conserved family of transcriptional regulators, defined by the presence of basic and helix-loop-helix domains (Massari and Murre, 2000) . ASCL proteins dimerize through their helix-loop-helix domains, which permits their basic domains to bind canonical E-box elements and thereby control transcription (Massari and Murre, 2000) . ascl1 (Johnson et al., 1990) and ascl2 (Johnson et al., 1990; Guillemot et al., 1994) function as lineagespecific transcription factors essential for development of the neurectoderm (Guillemot et al., 1993) and trophectoderm (Guillemot et al., 1994 (Guillemot et al., , 1995 , respectively. ascl1 is frequently expressed in human neoplasia with neuroendocrine features (Westerman et al., 2002) . By contrast, ascl2 has not been implicated in neoplastic transformation or progression, but there is circumstantial evidence to support a role for ascl2 in cancer. ascl2 resides at chromosome 11p15.5 and loss of imprinting at this locus is a frequent event in colorectal tumourigenesis (Cui et al., 1998) .
Using an in silico screen of Affymetrix HG-U133 oligonucleotide microarray data (Gene Logic s , Gaithersburg, MD, USA), we identified ascl2 as a gene with elevated expression in human colorectal neoplasms compared to all normal tissues. The aims of this study were to validate the expression profile of ascl2, to investigate the mechanisms responsible for the upregulation of ascl2 and to examine the role of ASCL2 in cancer.
Results

ascl2 expression in human tissues
A high level of ascl2 mRNA expression was observed in colorectal adenocarcinomas and other tumour types in the Gene Logic Affymetrix microarray database (Supplementary Figure 1) , with low levels of expression in all normal tissues. To confirm this expression profile, validation was sought from an independent series of gastrointestinal tissue RNA samples hybridized to the Affymetrix oligonucleotide microarray platform. Analysis of the 229215_at probeset revealed a statistically significant upregulation in the median expression level of ascl2 in primary colorectal adenocarcinomas (15.0-fold; Mann-Whitney U-test, Po0.0001), compared to normal mucosa ( Figure 1a ). Further validation was sought by quantitative reverse transcriptase (QRT)-PCR; increases in the median expression levels of ascl2 were observed in primary colorectal adenocarcinomas (9.7-fold; Mann-Whitney U-test, Po0.0001) compared to normal tissues (Figure 1b) . Upregulation of ascl2 mRNA was also observed in a proportion of human tumour cell lines by QRT-PCR (Figure 1c ). Moderate expression was observed in JEG3 choriocarcinoma cells, but no expression was seen in HELA cervical cancer cells, as previously reported (Westerman et al., 2001 ).
hasap does not contribute to the expression profile of ascl2 The primers and probes employed in the assessment of human ascl2 expression above recognize the second exon of ascl2. This region is common to both the putative long and short ascl2 mRNA transcripts (Westerman et al., 2001) . The long mRNA transcript encodes a putative open reading frame for an uncharacterized protein, human achaete-scute-associated protein (HASAP), which may make a contribution to the expression profile. Thus, northern hybridization was employed to investigate the relative contributions of the two transcripts. RNA from human tumour cell lines was probed with the cloned ascl2 open reading frame, postulated to recognize both splice variants. However, only a single band representing the shorter transcript (1470 bp) was observed ( Figure 1d ).
ascl2 localization in human tissues
Isotopic in situ hybridization (ISH) consistently localized the ascl2 transcript to the extra-villous trophoblasts of the placenta (Supplementary Figure 2) (Alders et al., 1997) . With the exception of placenta and intestine, no normal tissues represented in tissue microarrays (TMAs) or whole sections expressed ascl2 (data not shown). ascl2 expression was observed in the epithelial cells at the base of both small and large intestinal crypts (Figure 2a and b) . However, expression was very weak or absent in the majority of tissues, possibly due to the effects of tissue fixation (though, all cores were positive for b-actin expression (data not shown)) or the sensitivity of ISH. To confirm this observation, the luminal, middle and basal thirds of the normal colonic crypts were microdissected from a single tissue. QRT-PCR on RNA extracted from these microdissected cells localized ascl2 mRNA exclusively to the basal third of the crypt (>200-fold greater expression compared to the luminal third of the crypt (Supplementary Figure 3) ). ISH demonstrated that ascl2 mRNA expression was restricted to the epithelium, in benign and malignant intestinal neoplasms ( Figure  2c -e). The intensity of expression by neoplastic intestinal epithelial cells frequently exceeded the intensity observed at the base of normal intestinal crypts. The proportion of neoplastic intestinal tissues represented in TMAs that were positive for ascl2 expression (33-73%) was greater than the proportion of normal intestinal tissues (2-25%) (Figure 3a) .
The frequency of ascl2 mRNA expression was not significantly different among distinct subtypes of colorectal adenomas (52-71%), when comparing colorectal adenomas to adenocarcinomas (57 versus 65%) (Figure 3b ) or when comparing small and large intestinal cancers (54 versus 65%). Similarly, the frequency of ascl2 mRNA expression was not significantly different among different stages of colorectal adenocarcinomas (50-73%) (Figure 3b ). There was no association between the size of the colorectal adenoma and expression of ascl2 mRNA (Mann-Whitney U-test, P ¼ 0.27). No statistically significant associations were observed between ascl2 expression and patient demographics or tumour stage or histology (data not shown). These observations suggest that the upregulation of ascl2 transcription is an early event in neoplastic transformation.
Forty of 56 colorectal cancers (71%) represented in whole sections expressed ascl2 mRNA, consistent with the frequency of ascl2 expression in colorectal cancers represented in TMAs (65%). When present, ascl2
Figure 2 ascl2 mRNA expression by in situ hybridization in normal and neoplastic human tissues. In situ hybridization data are presented as representative bright field (BF) and dark field (DF) images demonstrating hybridization of antisense (AS) and sense (S) riboprobes as silver grain deposition. Expression of ascl2 is localized to the epithelial cells occupying the base of the large intestinal (a) and small intestinal (b) crypts (white arrows), but not further up the crypts (blue arrows). ascl2 mRNA is present throughout the dysplastic crypts (blue arrow) of certain colorectal adenomas (c), but expression is below the threshold for detection in adjacent normal crypts (c, white arrow). A proportion of adenocarcinomas arising in the small intestine (d) and large intestine (e) expressed ascl2 in the neoplastic cells. Sense ascl2 riboprobes did not show appreciable hybridization above background (c).
transcript was expressed throughout the majority of the neoplastic cells of the tumours (greater than 50% of neoplastic cells expressed ascl2 in 32 of 40 cancers (80%)), though, intratumoural variations in the intensity of expression were evident. There were no significant differences in the expression of ascl2 between primary and secondary cancers ( (Figure 4a) . A similar upregulation was observed by QRT-PCR on an independent series of tissues with 7.8-fold (Mann-Whitney U-test, P ¼ 0.036) and 2.7-fold (P ¼ 0.0079) increases in the median expression levels of ascl2 in tumours from apc min/ þ and apc
mice, respectively, compared to morphologically normal mucosa ( Figure 4b ). ISH conducted on morphologically normal intestine from wild-type, apc min/ þ and apc 1638N/ þ smad4 À/ þ adult mice showed evidence for ascl2 in the epithelium lining the base of the crypts (Figure 4c ). This was a consistent observation in all mouse intestinal tissues examined, and did not vary between wild-type, apc min/ þ and apc Figure 5 ) (Leow et al., 2004) . Both APC2 and LEF1 DN stably transfected cell lines showed evidence for a decrease in b-catenin-TCF/LEF activity by the TOPflash assay, compared to cells transfected with the empty vector (Leow et al., 2004) . Short-interfering RNA (siRNA) against b-catenin was also employed in seven colorectal cancer cell lines, showing evidence for a Achaete-scute like 2 in intestinal neoplasia AM Jubb et al decrease in ascl2 mRNA expression compared to controls ( Figure 6 ). To determine whether this relationship exists in situ, serial sections of several small intestinal TMAs (representing 73 adenocarcinomas) probed for ascl2 mRNA expression were labelled for b-catenin protein expression by immunohistochemistry ( Figure 7) . A statistically significant association between ascl2 mRNA expression and the nuclear localization of b-catenin (a surrogate for activated Wnt signalling) was observed ( Table 2 , w 2 test; Po0.0008). Similarly, colocalization of ascl2 mRNA and nuclear b-catenin protein was observed in five samples of normal intestinal mucosa and intestinal tumours from the apc min/ þ mouse ( Figure 7 ).
ascl2 promoter is a target of CpG methylation
Approximately 24% of small intestinal cancers that were positive for nuclear b-catenin did not express ascl2 mRNA (Table 2) . Epigenetic mechanisms, such as DNA methylation, were hypothesized to prevent the access of transcriptional activators to the ascl2 promoter, explaining the lack of an association in these cases. Methylation sensitive PCR (MSP) primers were designed to examine a region within the ascl2 promoter CpG island, À453 to À295 bp relative to the ascl2/hash2 ORF transcriptional start site. MSP primers for ascl2 were first validated on HCT15 cells, known to express high levels of ascl2 mRNA and HCT116 cells, known to express low levels of ascl2 mRNA and reported to display a defect in DNA methylation. HCT15 cells showed evidence for a completely unmethylated CpG island at the ascl2 locus. By contrast, HCT116 showed evidence for a completely methylated CpG island at the ascl2 locus ( Figure 8a ). To investigate whether the DNA methylation observed at the ascl2 locus was functionally associated with the repression of gene expression, HCT116 cells were treated with 5-aza-2 0 deoxycytidine (AZA), an inhibitor of the DNMT enzymes. A dose-dependent increase in Figure 4 Expression of ascl2 mRNA in normal and neoplastic mouse tissues. ascl2 expression was assessed using the Affymetrix MOE430 GeneChip (a), showing statistically significant increases in the median probeset signal intensity for apc min/ þ (4.6-fold) and apc 1638N/ þ smad4 À/ þ (27.0-fold) mouse tumours relative to corresponding morphologically normal mucosa. These findings were confirmed by quantitative (Q)RT-PCR (b), showing 7.8-and 2.7-fold median increases in the expression of ascl2 for apc min/ þ and apc 1638N/ þ smad4 À/ þ tumours. Data are presented as box-whisker plots (refer to Figure 1 ). QRT-PCR fold changes were normalized to the level of rpl19 expression, and relative to the mean expression of the corresponding normal tissues. (c and d) In situ hybridization demonstrating ascl2 expression in the intestine of apc 1638N/ þ smad4 À/ þ mice. Brightfield (BF) and darkfield (DF) images show silver grains overlying regions of isotopic probe hybridization, corresponding to mRNA expression. ascl2 mRNA expression was localized to the epithelium, with signal restricted to cells at the base of normal crypts (c), and throughout the neoplastic epithelium (d).
the level of ascl2 mRNA expression was accompanied by an increasing demethylation of the ascl2 promoterregion CpG island ( Figure 8b ). Histone deacetylation and DNA methylation are cooperative mechanisms that are believed to regulate epigenetic transcriptional silencing. To investigate the contribution of histone deacetylation to the epigenetic silencing of ascl2 transcription, an inhibitor of the histone deacetylases, trichostatin-A (TSA), was employed. However, TSA did not affect ascl2 expression until dose-limiting toxicity was reached (Figure 8b ).
ascl2 knockdown results in a G2/M arrest Knockdown of ascl2 expression in HCT15 and HT29 cell lines was associated with an increase in the proportion of cells in the G2 phase of the cell cycle (Figure 9a ), consistent with a G2/M checkpoint arrest. No effect of ascl2 knockdown was seen in HCT116 cells, which do not express ascl2 RNA. Survivin and cdc25b are reported to be targets of Wnt signalling, that are overexpressed in colorectal cancer compared to normal colon and promote progression through the G2/M checkpoint (Hernandez et al., 2001; Zhang et al., 2001; Rodel et al., 2005) . Therefore, it was hypothesized that the G2/M arrest seen on knockdown of ascl2 might be secondary to the transcriptional regulation of survivin and/or cdc25b by ASCL2. QRT-PCR revealed significant decreases in survivin and cdc25b mRNA expression in HCT15 cells treated with ascl2 siRNA, compared to controls (Figure 9b ). Moreover, analysis of Affymetrix microarray data from the Gene Logic s database revealed that cdc25b and survivin expression are both significantly elevated in human colorectal cancers relative to normal colon (Figure 9c and d) . Survivin and cdc25b expression levels were statistically significantly correlated with ascl2 expression in this data set (Figure 9c and d).
ascl2 is not imprinted
To investigate the imprinting status of ascl2 in human intestinal tissue, a restriction-fragment length polymorphism assay was designed to investigate a SacII site in exon II of ascl2. Matched normal colon mucosa and colorectal cancer samples were investigated, in addition to normal colon mucosa from patients without colorectal cancer. Of these patients, cases were identified that were heterozygous at the DNA level in normal tissues (five of 10 cancer patients and five of 10 patients without cancer). The zygosity of each case was next assessed at the RNA level, to determine whether the transcript was homozygous (mono-allelic expression) or heterozygous (biallelic expression). In all normal tissues, the RNA was heterozygous, that is, expression was biallelic (Table 3) . The same observation was made for all cancer tissues, with the exception of a single tissue that appears to have undergone loss of heterozygosity at the ascl2 locus. All cancers showed upregulation of ascl2 relative to matched normal tissues by QRT-PCR (data not shown). ascl2 mRNA expression was also observed by ISH in the extravillous trophoblasts from both partial (2:1 ratio of male:female DNA) and complete (all DNA derived from the male) hydatidiform moles, an identical pattern to that seen in normal placenta (Supplementary Figure 4) .
Discussion
ASCL2 is a transcription factor responsible for the differentiation of the trophoblast lineage in normal human placenta (Guillemot et al., 1994) . Screening the Gene Logic s database for genes with elevated expression in human colorectal neoplasia, relative to expression in normal human tissues, identified ascl2. Further validation indicates that ascl2 is overexpressed as a consequence of dysregulated Wnt signalling from an early stage in intestinal neoplasia. In addition, preliminary in vitro data suggest that decreased expression of ascl2 results in arrest at the G2/M cell cycle checkpoint.
Numerous large-scale expression-profiling studies have failed to identify an increase in ascl2 expression in colorectal neoplasia. This may be explained, in part, by the absence of a probeset specific for ascl2 in the earlier Affymetrix GeneChips. However, recently Banerjea et al. (2004) observed that the mean expression of ascl2 was 4.3-fold greater in microsatellite stable colorectal cancers compared to cancers with high-level microsatellite instability using Affymetrix HG-U133 GeneChips. To our knowledge, this is the only publication to date that specifically cites ascl2 expression in colorectal cancers and provides external validation for our findings. Herein, we have used multiple lines of evidence to demonstrate that Wnt signalling in normal and neoplastic intestine regulates ascl2 transcription. Much of this evidence is circumstantial, and may be explained by a common regulator for ascl2 and b-catenin, regulation of b-catenin by ascl2 or progression of tumours with dysregulated b-catenin along a pathway that frequently dysregulates ascl2 expression by an independent mechanism. No evidence has been presented to confirm that the TCF4 consensus binding sequences in the ascl2 promoter are functional. Moreover, the APC2, LEF1 DN and b-catenin proteins may have functions distinct to the transduction of Wnt signals. When the evidence is considered as a whole, though, it strongly suggests that ascl2 is a transcriptional target of Wnt signalling in the intestine. During the conduct of our research, Sansom et al. (2004) reported the phenotype of a conditional apc
mouse model, where the truncation of apc was mediated by the Lox-Cre system. When apc was truncated ascl2 expression was upregulated 22.2-fold relative to expression in controls (Sansom et al., 2004) , providing independent in vivo validation of the data presented herein. The data provided by Sansom et al. suggests that ascl2 is strongly regulated by Wnt signalling with a much greater reported induction in expression with loss of apc than other known Wnt targets such as axin2, ephB2, cyclin D2 and CD44.
It is evident from the serial analysis of ascl2 and b-catenin in small intestinal cancers that ascl2 is expressed in certain colorectal cancers without nuclear b-catenin (B10%) and ascl2 is not always expressed in cancer cells that show evidence for nuclear b-catenin (B16%). This suggests that other mechanisms may regulate ascl2 expression in the colon. Our observations suggest that ascl2 expression may be repressed in vitro by methylation of the promoter CpG island. Likewise, activation of oncogenic signalling pathways that act through cMyc may upregulate ascl2 expression in cancer cell lines (Fernandez et al., 2003) . Further work is needed to validate the significance of these observations to primary human cancers.
Loss of imprinting at the 11p15.5 locus is a frequent event leading to the overexpression of genes in colorectal cancer (Cui et al., 1998) . Therefore, loss of imprinting of ascl2 was hypothesized to contribute to the upregulation of ascl2 transcription. There is strong evidence to suggest that ascl2 is imprinted in the mouse (Guillemot et al., 1994 (Guillemot et al., , 1995 . However, the evidence that supports imprinting of the human ascl2 gene is more tenuous and is inferred from the failure to observe ascl2 mRNA in androgenous hydatidiform moles (Alders et al., 1997) . Others have published contrary data, using a restrictionfragment length polymorphism assay to demonstrate biallelic expression of ascl2 in the placenta (Miyamoto et al., 2002) . These data are in agreement with our findings on human tissues from the large intestine. Moreover, experiments on hydatidiform moles reported herein demonstrate a similar pattern of ascl2 expression to that seen in normal human placenta. The reason(s) for the lack of concordance between our observations and the observations of Alders et al. (1997) are not clear, but may be explained by methodological discrepancies or differences in tissue quality. Our interpretation indicates that the increase in ascl2 expression seen in colorectal cancer cannot be due to loss of imprinting. Such discordance between human and mouse is not an unprecedented; a recent review described 49 transcriptional units with discordant imprinting between mouse and man (Morison et al., 2005) . In certain instances the discordance is hypothesized to be due to the absence of a neighbouring imprinted gene or regulator that affects the imprinting of the gene of interest in cis. Further work is needed to determine the exact mechanism of the discordance for ascl2 and whether it represents a true lack of imprinting or a relaxation of imprinting from an earlier stage of development.
One major limitation of this analysis is the failure to demonstrate ASCL2 protein expression in normal and neoplastic tissues. Antibodies described in the literature have not been properly validated and there are no commercially available reagents. Our own attempts to generate antibodies against ASCL2 have failed to recognize endogenous ASCL2 protein with adequate specificity. Further work is necessary to develop reagents that can validate this aspect of the ASCL2 expression profile.
Preliminary in vitro data suggest that ascl2 may control the G2/M cell cycle checkpoint by regulating the expression of survivin and cdc25b (Figure 9 and Supplementary Figure 5) . Both survivin and cdc25b are reported to be clinically important in colorectal cancer. Survivin is known target of Wnt signalling (Zhang et al., 2001 ) and a putative radioresistance factor in rectal cancer, which may predict local failure of rectal malignancies after chemoradiotherapy and surgical resection (Rodel et al., 2005) . cdc25b is overexpressed in 56% of colorectal cancers and expression may predict overall survival (Hernandez et al., 2001) . Together with the localization of ascl2 expression to the putative stem cell niche in the intestinal crypt and its upregulation in the early stages of neoplasia, these data suggest a role for ascl2 in promoting cell proliferation. Associations with markers of predictive and prognostic significance also suggest that ascl2 expression and the manipulation of ascl2 expression may be clinically relevant in the management of colorectal cancer. These data must be considered preliminary, however, until it has been validated in vivo. Olmeda et al. (2003) have proposed that b-catenin activation leads to a G2/M cell cycle arrest in the in vitro culture of keratinocyte cells. This appears at odds with the data presented herein. However, the authors also report that SW480 colorectal cancer cells with INK4a (Myohanen et al., 1998) ; HCT15 cells are reported to carry a 'high-density of methylation' at p16
INK4a as observed (Zheng et al., 2000) . HCT15 cells that express high levels of ascl2 showed evidence for unmethylated DNA only. By contrast, HCT116 cells that do not express ascl2 showed evidence for methylated DNA only. (b) Using 5-aza-2 0 deoxycytidine (AZA) the expression of ascl2 mRNA could be induced in vitro in HCT116 cells. Note that the AZA did not diminish the methylated DNA signal for ascl2 (methylation sensitive PCR, MSP); the reason for this is not clear but may reflect the high sensitivity of the assay. A similar induction of ascl2 and expression can be observed in cells treated with trichostatin A (TSA). However, this is not apparent until levels of toxicity are reached. The induction of sfrp1 expression is used as a positive control. Western blots demonstrate an appropriate reduction in the amount of DNMT1 protein in cells treated with AZA and an appropriate increase in acetylated histones in cells treated with TSA. L, ladder; s.e.m., standard error of the mean. dysregulated b-catenin control are insensitive to lithiuminduced G2/M cell cycle arrest and do not fit with their hypothesis. Thus, it is conceivable that b-catenin may play an opposite role in colorectal neoplasia, which may act, in part, through the induction of ascl2 expression. It must be emphasized, though, that ascl2 is not essential for progression through the G2/M checkpoint, as HCT116 cells do not express ascl2 and siRNA against ascl2 has no effect on this cell line.
In summary, ascl2 is upregulated at all stages of neoplasia arising in the glandular epithelium of the small and large intestine in man and mouse. Preliminary data suggest a role for ascl2 in cell cycle progression. Nevertheless, further work is needed to validate these observations in vivo.
Materials and methods
Oligonucleotide microarrays
Fresh, frozen and/or RNAlater-treated tissue samples were collected from colorectal (16 normals and 36 primary adenocarcinomas) surgical resection specimens at the Leeds and Sheffield Teaching Hospitals NHS Trusts (all tissues from these sources were anonymized and their use was approved by the Leeds Teaching Hospitals NHS Trust research ethics committee). RNA was extracted by caesium chloride precipitation according to standard protocols. Three apc min/ þ and two apc 1638N/ þ smad4 À/ þ mice were euthanized at approximately 3 months of age. Five regions of normal mucosa were resected from each apc min/ þ mouse and two from each apc 1638N/ þ smad4 À/ þ mouse, representing the full length of the intestine. In addition, seven intestinal tumours were resected from each apc min/ þ mouse and three from each apc
All animal experiments were conducted in accordance with the Institutional Animal Care and Use Committee (Memphis, TN, USA) regulations. Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA, USA). RNA amplification, labelling and hybridization have been described elsewhere (Yang et al., 2002) . Affymetrix (Santa Clara, CA, USA) HG-U133 GeneChips were employed for human tissues (human ascl2 probeset 229215_at) and MOE430A GeneChips were employed for mouse tissues (mouse ascl2 probeset 143018_at). Data analysis was performed using Resolver (version 4.0, Rosetta Biosoftware, Seattle, WA, USA).
Quantitative RT-PCR HELA, KM12, KM20L2 and HCC2998 cell lines were obtained from the NCI. All other cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). Fresh-frozen large intestinal tissues (16 normal and 29 primary adenocarcinomas) were obtained from the Leeds Teaching Hospitals NHS Trust. One apc min/ þ and five apc 1638N/ þ smad4 À/ þ mice were euthanized at approximately 3 months of age. Three regions of normal mucosa were resected from the apc min/ þ mouse and one from each of the apc 1638N/ þ smad4 À/ þ mice, representing the full length of the small and large intestines. In addition, five intestinal tumours were resected from the apc min/ þ mouse and one from each of the apc 1638N/ þ smad4 À/ þ mice. All RNA was prepared using RNA STAT-60 (Tel-Test, Friendswood, TX, USA) and DNaseI-treated with DNA-free (Ambion, Austin, TX, USA).
Total RNA (100 ng) was amplified in a 50 ml PCR according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). Primer sequences can be found in Supplementary Table 2 . Thermal cycling and quantitative analysis were carried out using an ABI7700 prism running Sequence Detection System version 1.9 (Applied Biosystems). An initial incubation for 30 min at 481C was followed by a denaturation step at 941C for 10 min and 40 cycles of 941C for 45 s and 601C for 1 min. All reactions were performed in triplicate, in addition to a control reaction omitting RT.
In situ hybridization on formalin-fixed, paraffin embedded tissues Unless otherwise stated all tissues were obtained from anonymized samples acquired from multiple sources in the Genentech pathology archive. Analyses included several whole sections normal placenta at term (n ¼ 3), a partial hydatidiform mole (n ¼ 1), a complete hydatidiform mole (n ¼ 1) and normal retina (n ¼ 1). In addition, in situ hybridization was performed on a series of 23 primary colorectal cancers and 25 metastases (22 lymph nodes and three hepatic), representing 25 patients. An additional eight unmatched hepatic metastases from nine patients were also included. TMAs were constructed from triplicate tissue cores (0.6 mm in diameter) as described previously (Jubb et al., 2003) . A 'normal' TMA represented three samples of each: aorta, bladder, brain, breast, colon, heart, kidney, lung, lymph node, ovary, pancreas, placenta, prostate, seminal vesicles, skin, small intestine, spleen, stomach, testis, thyroid and tonsil. 'Adenoma' TMAs (Leeds Teaching Hospitals NHS Trust) represented 22 normal colon samples, 48 flat adenomas, five villous adenomas, 27 tubulovillous adenomas, 93 tubular adenomas and 14 adenomas adjacent a Dukes' stage A adenocarcinoma. 'Small intestine' TMAs (Leeds Teaching Hospitals NHS Trust) included ampullary (four normal, four adenocarcinoma), periampullary (five normal, six adenocarcinoma), duodenal (31 normal, 33 adenocarcinoma), jejunal (46 normal, 50 adenocarcinoma) and ileal (31 normal, 31 adenocarcinoma) tissues. 'Large intestine' TMAs included 327 colorectal cancers (Leeds Teaching Hospitals NHS Trust); matched normal mucosa was available for 165 of these cases. Analyses were also conducted on formalin-fixed, paraffin-embedded tissues obtained from wild-type (two small intestinal tissue samples from two mice), apc min/ þ (four jejunal and one rectal tissue sample from three mice) and apc 1638N/ þ smad4 À/ þ (six small intestinal tissue samples from six mice) mice.
cDNA probe templates were amplified from human colon cancer (human ascl2, hasap and b-actin) and mouse 11-day embryo (mouse ascl2) marathon-ready cDNA by PCR. Primers sequences are provided in Supplementary Table 3 . Isotopic probe labelling, hybridization, washing and developing have been described elsewhere (Jubb et al., 2003) . Tissues subjected to in situ hybridization for b-actin and ascl2 were scored positive or negative by a single pathologist for the presence or absence of the hybridized antisense probe, throughout the tissue (b-actin) or in >10% of the epithelium (ascl2). In addition, the percentage of tumour cells scored positive for ascl2 mRNA expression was recorded for whole sections of colorectal cancer. In all TMAs, the score from the highest expressing core was used to represent each patient.
Northern hybridization
Poly(A) þ RNA was purified from total RNA of HCT15, DLD1, JEG3 and HCT116 using FastTrack 2.0 (Invitrogen). The ascl2 open reading frame (1394-2157 bp of Genbank AF442769) was amplified by PCR using primers: sense 5 0 -CGGGCTCCAGACGACCTAGGAC-3 0 , antisense 5 0 -CTCA TAGGTCGAGGGCGCTCAGTA-3 0 . A probe specific for b-actin was similarly amplified using primers: sense 5 0 -GCC GGGACCTGACTGAC-3 0 , antisense 5 0 -AACAAATAAAGC CATGCCAAT-3 0 (618-1291 bp of Genbank NM_001101). The PCR product was resolved on an agarose gel and the appropriate band was gel purified. The probe was labelled with This result is likely to be due to loss of heterozygosity at the ascl2 locus (chromosome 11p15.5).
[a 32 P]-dCTP using random hexamers. Of poly(A) þ RNA, 2 mg were electrophoresed, blotted, hybridized, washed and exposed to film according to standard protocols.
Expression of ascl2 mRNA in microdissected colonic crypt regions Laser microdissection was carried out on tissue sections from an anonymized fresh-frozen normal human colon sample (Genentech archive) to isolate the basal, middle and luminal thirds of the colonic crypt epithelium (SLm-cut instrument (MMI, Glattbrugg, Switzerland) ). Approximately 2000 cells were dissected from each third of the crypt. RNA was extracted using the Picopure RNA kit (Arcturus, Mountain View, CA, USA) and amplified in two rounds using MessageAmp II (Ambion). Amplified RNA was subjected to QRT-PCR as described above, with 20 ng of amplified RNA in each 50 ml reaction.
Inhibition of Wnt signalling with APC2 and LEF1 DN pcDNA3 vectors (Invitrogen, Carlsbad, CA, USA) containing either the APC2 coding sequence or the coding sequence for the LEF1 dominant-negative isoform LEF1 DN were the generous gift of B Rubinfeld (Genentech). Stably expressing HT29 cell clones were generated by C Leow (Genentech) as described elsewhere (Leow et al., 2004) . Cells were harvested for RNA and analysed by QRT-PCR as described above. Inhibition of b-catenin-TCF/LEF target binding was confirmed by a TOPflash luciferase assay described elsewhere (Leow et al., 2004) .
Inhibition of Wnt signalling with siRNA against b-catenin siRNAs were obtained from Ambion for b-actin and b-catenin. siRNA sequences were not available from Ambion for b-actin (designed to 5 0 region of Genbank NM_001101) or b-catenin (designed to exons 4/5 of Genbank NM_001904). Seven colorectal cancer cell lines (COLO205, HCC2998, HT29, HCT15, KM12, DLD1 and T84) were transfected with siRNA to b-actin or b-catenin to a final concentration of 50 nM. Untransfected cells were plated in parallel to transfected cells for a comparison of gene expression levels. Cells were harvested for RNA 48 h after transfection and analysed by QRT-PCR (above). Alternatively, total protein was harvested using the PARIS buffer (Ambion) and expression assessed by Western blotting (below). All experiments were repeated twice under identical conditions.
Restriction fragment length polymorphism assay
Reactions were designed to assess a polymorphic SacII restriction site in exon 2 of ascl2 (Miyamoto et al., 2002) . RNA and DNA were extracted from 10 matched pairs of normal colorectal mucosa and colorectal cancer (Leeds Teaching Hospitals NHS Trust) and 10 normal colorectal samples from patients without evidence of colorectal neoplasia (multiple sources, Genentech archives) and T84 colorectal cancer cells, using RNA and DNA STAT-60, respectively. Half a microgram of each DNA sample was amplified by PCR. Sense and antisense primer sequences were 5 0 -CGGCCCA GCCTGACCAATG-3 0 and 5 0 -GAAGCCGCCAGCCCT TATG-3 0 , respectively. RNA samples were all DNaseI-treated. RNA was reverse-transcribed and PCR-amplified in a single step (titanium taq one-step RT-PCR kit, BD Clontech). Primer sequences were, sense: 5 0 -GAGCCTCAGCCCCGGAAGC-3 0 and antisense: 5 0 -CGCCCCACTGCAGTCGAGAAG-3 0 . Negative control reactions omitting the RT were included for each sample. PCR products were gel purified and digested overnight with SacII. Of each product, 1 ml was resolved on a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Expected fragments were 68, 45 and 23 bp (DNA) or 255, 164 and 91 bp (RNA). Expression of ascl2 RNA was assessed by QRT-PCR in all tissues examined (see above).
Western blotting
Western blotting was performed according to the instructions supplied by the primary antibody manufacturer. Primary antibodies employed herein included rabbit polyclonal anti-bcatenin, antihistone H3, antiacetyl(Lys9)-histone H3 (Cell Signaling Technology, Beverly, MA, USA) mouse monoclonal anti-a-tubulin (Sigma-Aldrich, St Louis, MO, USA) and rabbit polyclonal anti-DNMT1 (New England Biolabs, Beverly, MA, USA).
Immunohistochemistry
Immunohistochemistry for b-catenin was performed on serial sections of tissues investigated for ascl2 expression by in situ hybridization, including all apc min/ þ tissues and TMAs representing 73 human small intestinal adenocarcinomas. Immunohistochemistry was performed as described elsewhere (Jubb et al., 2003) with a mouse anti-b-catenin monoclonal antibody (clone 14, BD Pharmingen, San Diego, CA, USA) or naive immunoglobulins at 1 mg ml
À1
. In all TMAs, the score from the highest expressing core was used to represent each patient. Tumours were considered positive for b-catenin expression if >10% of neoplastic cells showed nuclear localization.
Methylation-sensitive PCR DNA was extracted from HCT15 and HCT116 cell lines using DNA STAT-60. Bisulphite modification was performed on 100 mg of DNA from each sample using the CpGenome DNA modification kit (Serologicals, Norcross, GA, USA), according to the manufacturer's instructions. Each modified DNA sample was amplified using primers specific for a methylated or unmethylated sequence in the human ascl2 promoter (Supplementary Table 4 ). Primers specific for p16
INK4a were employed as controls for the PCR reaction and complete bisulphite modification. For ascl2, each 50 ml reaction contained 1 Â PCR buffer II, 4 mM MgCl 2 , 1.6 mM dNTPs, 22 pmol each primer, 1 U amplitaq gold (Applied biosystems). Reactions were hot-started at 951C for 10 min and cycled 35 Â at 951C for 45 s, 601C for 45 s and 721C for 2 min. After a final extension at 721C for 10 min, reactions were cleaned up with the QIAquick kit and resolved on a 2% agarose gel. In all ascl2 MSP experiments, water-only, and HCT15 and HCT116 cell line DNA were included as negative, completely unmethylated and completely methylated controls. MSP for p16 INK4a was performed as described elsewhere (Herman et al., 1996) .
In vitro treatment of cell lines with DNA methyltransferase and histone deacetylase inhibitors TSA or AZA were added to HCT116 cell media at several concentrations within the range: 0-10 mM in DMSO. Cells were then incubated at 371C for 48 h, when total RNA and DNA were harvested using RNA/DNA STAT-60 for analysis by QRT-PCR and MSP. All experiments were repeated twice under identical conditions. To confirm the biological activity of the inhibitors in vitro, replicate HCT116 cultures, set up in parallel to the experiment described above, were treated with either DMSO or 10 mM of either AZA or TSA. At the 48 h timepoint, total protein was harvested using the PARIS buffer to permit the assessment of DNMT1 and acetylated histone levels by Western blotting.
Assessing ascl2 function using siRNA siRNAs were available from Ambion for ascl2: sense 5 0 -GCAAGAAGCUGAGCAAGGUtt-3 0 , corresponding to nucleotides 1805-1823 of Genbank AF442769. To assess the impact of siRNA against ascl2 on the cell cycle, colorectal cancer cell lines HCT15, HT29 and HCT116 were treated with ascl2 siRNA as described above, using b-actin siRNA and no siRNA as controls. Cells were harvested at 50% confluency, filtered, fixed in ethanol, pelleted, resuspended in a propidium iodide staining solution and incubated at 371C for 15 min.
Staining was assessed by fluorescent automated cell sorting using an Epics X-L (Beckman Coulter) and analysis was performed with FloJo version 6.2 (Tree Star, San Carlos, CA, USA). Cell cycle analyses were repeated under identical conditions. To assess the impact of siRNA against ascl2 on the expression of survivin and cdc25b, HCT15 cells were treated with ascl2 siRNA as described above, using b-actin siRNA and no siRNA as controls. Cells were harvested for RNA, using RNA STAT-60, 48 h after transfection and analysed by QRT-PCR as described above.
